Neuromeda - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 385,740 | 472,874 | 431,146 | 542,682 | 502,188 | 400,631 | 493,624 | 534,544 |
| Profit before tax | -21,174 | -1,497 | 27,749 | 9,703 | -2,338 | -38,527 | 526 | -6,177 |
| Net profit | -21,174 | -1,497 | 26,419 | 9,254 | -2,338 | -38,527 | 473 | -6,177 |
| Equity | -19,571 | -21,068 | 5,352 | 4,606 | 229,229 | -29,806 | -29,333 | -35,510 |
| Liabilities | 83,076 | 80,079 | 85,290 | 49,199 | 42,785 | 66,898 | 75,393 | 76,125 |
| Non-current assets | 50,917 | 32,573 | 14,828 | 19,911 | 233,546 | 20,817 | 15,344 | 12,226 |
| Current assets | 12,588 | 26,438 | 75,814 | 33,894 | 38,332 | 15,940 | 30,451 | 26,795 |
| Total assets | 63,505 | 59,011 | 90,642 | 53,805 | 271,878 | 36,757 | 45,795 | 39,021 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 64,686 | 74,773 | 81,882 |
| Social insurance contributions | - | - | - | - | - | 73,847 | 90,127 | 94,085 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +3.3% | +22.6% | -8.8% | +25.9% | -7.5% | -20.2% | +23.2% | +8.3% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -33.3% | -2.5% | 29.1% | 17.2% | -0.9% | -104.8% | 1.0% | -15.8% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | - | 493.6% | 200.9% | -1.0% | - | - | - |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -5.5% | -0.3% | 6.1% | 1.7% | -0.5% | -9.6% | 0.1% | -1.2% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | -5.5% | -0.3% | 6.4% | 1.8% | -0.5% | -9.6% | 0.1% | -1.2% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | 15.9 | 10.7 | 0.2 | - | - | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 7,418 | 9,585 | 8,265 | 11,247 | 11,435 | 10,779 | 12,905 | 15,236 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Neuromeda - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-11-18 | 2025-12-14 | 0.14 |
| 2025-10-23 | 2025-11-13 | 0.15 |
| 2025-09-16 | 2025-09-24 | 56.54 |
| 2022-01-27 | 2022-02-14 | 0.13 |
Neuromeda - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-12-15 | 2025-12-15 | 18.9 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Neuromeda, UAB, company code 135042960, is a Private Limited Liability Company engaged in medical specialists activities. In 2025, revenue reached €534.5K, up 8.3% year on year and 33.4% over two years, showing steady top-line growth. Profitability remained fragile: after a small net profit of €473 in 2024, the company returned to a net loss of €6.2K in 2025, with a margin of -1.2%. This followed a larger loss of €38.5K in 2023, so the three-year pattern shows improving results in 2024 and a weaker outcome in 2025. The balance sheet remained pressured, with total assets of €39.0K, equity at -€35.5K and liabilities of €76.1K at the end of 2025. Long-term assets stood at €12.2K and short-term assets at €26.8K. Revenue per employee was €15.3K, while profit per employee was -€176. Asset turnover was high at 13.70x, indicating strong revenue generation relative to the asset base, although negative equity means leverage and return measures should be interpreted cautiously.